The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Cirrhosis is a chronic condition that can lead to liver failure. Currently, the viable option for decreasing mortality is liver transplantation. However, transplant surgery is highly invasive. Therefore, cell-based therapy has been developed as an alternative. Based on promising findings from preclinical research, some new trials have been registered. One of them was autologous bone marrow cell infusion therapy and found that ameliorating liver fibrosis activated liver regeneration. Now, majority of trials focus on low-immunogenicity mesenchymal stem cells (MSCs) appropriate for allogeneic administration. However, despite about 20 years of research, only a limited number of cell-based therapies have entered routine practice. Furthermore, potential shortcomings of cell-based therapy include a limit on the number of cells, which may be administered, as well as their failure to infiltrate target organs. On the other hand, these research show that MSCs act as “conducting cells” and regulate host cells including macrophages via extracellular vesicles (EVs) or exosome signals, leading to ameliorate liver fibrosis and promote regeneration. Therefore, the concept of cell-free therapy, which makes use of cell-derived EVs or exosomes, is attracting attention. Cell-free therapies may be safely administered in large doses and are able to infiltrate target organs. However, development of cell-free therapy exhibits its own set of challenges and such therapy may not be completely curative in the context of liver disease. This review describes the history of cell-based therapy research and recent advances in cell-free therapy, as well as discussing the need for more effective therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Macrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335 · cited 1×
“Research has focused largely on hematopoietic stem cells,(32,33) mesenchymal stem cells (MSCs),(34-36) and bone marrow-derived macrophages.(37,38) In particular, MSCs and macrophages have been the mainstays of cell-based therapy, and their characteristics as well as relevant clinical trials will be described in the fi…”
BackgroundBurden of liver diseases in the world
Asrani, S. K., Devarbhavi, H., Eaton, J., & Kamath, P. S. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.09.014 · Cited by 3,783
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair
Duffield, J. S., Forbes, S. J., Constandinou, C. M., Clay, S., Partolina, M., Vuthoori, S., Wu, S., Lang, R., & Iredale, J. P. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200522675 · Cited by 1,649 · cited 4×
“The same factors (TSG-6, PGE2, and IL-13) are also produced by MSCs, and contribute to host macrophages polarization in a similar manner.63-65 Furthermore, we have previously reported that MSCs promote liver infiltration by host neutrophils and monocytes, which contribute to fibrosis amelioration via production of MMP…”
BackgroundInfluentialPlasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications
Wang, Y., Chen, X., Cao, W., & Shi, Y. (2014) · Nature Immunology · doi:10.1038/ni.3002 · Cited by 1,452
Zhou, B. O., Yue, R., Murphy, M. M., Peyer, J. G., & Morrison, S. J. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.06.008 · Cited by 1,381 · cited 2×
“, CD73, CD90, and CD105) is noted on MSCs, and they are able to differentiate into adipocytes, osteoblasts, and chondroblasts under the appropriate conditions.(34,35) It appears that the major therapeutic (anti-inflammatory, antifibrotic, anti-oxidant, and angiogenic) effects of MSCs are due to their soluble products,…”
BackgroundLiver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis
Mokdad, A. A., Lopez, A. D., Shahraz, S., Lozano, R., Mokdad, A. H., Stanaway, J., Murray, C. J., & Naghavi, M. (2014) · BMC Medicine · doi:10.1186/s12916-014-0145-y · Cited by 1,129 · cited 1×
“Therefore, the number of deaths attributable to cirrhosis remains high.(8) Although liver transplantation is currently the only curative treatment for decompensated cirrhosis,(9,10) significant limitations include a shortage of donors, high cost, highly invasive nature of the surgery, use of immunosuppressive agents t…”
BackgroundHenderson, N. C., Arnold, T. D., Katamura, Y., Giacomini, M. M., Rodriguez, J. D., McCarty, J. H., Pellicoro, A., Raschperger, E., Betsholtz, C., Ruminski, P. G., et al. (2013) · Nature Medicine · doi:10.1038/nm.3282 · Cited by 866
Mesenchymal Stem/Stromal Cells (MSCs): Role as Guardians of Inflammation
Prockop, D. J., & Youn Oh, J. (2012) · Molecular Therapy · doi:10.1038/mt.2011.211 · Cited by 816 · cited 1×
“Since recent studies suggest that MSC-conditioned medium (or exosomes present therein) are as effective as MSCs themselves, soluble factors are currently of great interest regarding their regenerative potential in the therapy of cirrhosis.(7,34-36,57-60) Via soluble factors, MSCs may have therapeutic effects in cirrho…”
BackgroundMesenchymal stem cell–educated macrophages: A novel type of alternatively activated macrophages
Kim, J., & Hematti, P. (2009) · Experimental Hematology · doi:10.1016/j.exphem.2009.09.004 · Cited by 785
Cited by
Kou, M., Huang, L., Yang, J., Chiang, Z., Chen, S., Liu, J., Guo, L., Zhang, X., Zhou, X., Xu, X., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05034-x · Cited by 640
Psaraki, A., Ntari, L., Karakostas, C., Korrou‐Karava, D., & Roubelakis, M. G. (2022) · Hepatology · doi:10.1002/hep.32129 · Cited by 145
García-Bernal, D., García-Arranz, M., Yáñez, R. M., Hervás-Salcedo, R., Cortés, A., Fernández-García, M., Hernando-Rodríguez, M., Quintana-Bustamante, Ó., Bueren, J. A., García-Olmo, D., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.650664 · Cited by 138
Molecular mechanisms in liver repair and regeneration: from physiology to therapeutics
Ma, X., Huang, T., Chen, X., Li, Q., Liao, M., Fu, L., Huang, J., Yuan, K., Wang, Z., & Zeng, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02104-8 · Cited by 133
Current evidence on posthepatectomy liver failure: Comprehensive review
Sparrelid, E., Olthof, P. B., Dasari, B. V. M., Erdmann, J. I., Santol, J., Starlinger, P., & Gilg, S. (2022) · BJS Open · doi:10.1093/bjsopen/zrac142 · Cited by 88
Mohammadi, M. H., Okhovatian, S., Savoji, H., Campbell, S. B., Lai, B. F. L., Wu, J., Pascual‐Gil, S., Bannerman, D., Rafatian, N., Li, R., et al. (2022) · Advanced Biology · doi:10.1002/adbi.202101165 · Cited by 28
Wang, H., Yao, W., Wang, Y., Dong, H., Dong, T., Zhou, W., Cui, L., Zhao, L., Zhang, Y., Shi, L., et al. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03494-2 · Cited by 28
Yarahmadi, A., Dorri Giv, M., Hosseininejad, R., Rezaie, A., Mohammadi, N., Afkhami, H., & Farokhi, A. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1472679 · Cited by 21
Pretreatment of UC-MSCs with IFN-α2 improves treatment of liver fibrosis by recruiting neutrophils
Xie, Y., Yao, J., Yan, M., Lin, Y., Wei, J., Wang, H., Mao, Y., Liu, P., & Li, X. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04732-0 · Cited by 9
Noorzehi, G., Pasbakhsh, P., Taghizadeh, F., Alikarami, A., Kashani, I. R., & Mojaverrostami, S. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118027 · Cited by 3
Metadata
- Authors
- Watanabe, Y., Tsuchiya, A., & Terai, S.
- Venue
- Clinical and Molecular Hepatology
- Published
- 2021-01-01
- Volume
- 27
- Issue
- 1
- Pages
- 70-80
- ISSN
- 2287-2728 (ISSN-L)
- 2287-285X
- OpenAlex
- W3111347985
- Cited by
- 144
- References
- 27
- FWCI
- 7.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.